Erratum: Peroxisome Proliferator-Activated Receptor-γ1 Gene Therapy Attenuates Atherosclerosis and Stabilizes Plaques in Apolipoprotein E-Deficient Mice (Human Gene Therapy (2008) 19:3 (287-299) DOI: 10.1089/hum.2007.0142);Peroxisome proliferator-activated receptor-γ1 gene therapy attenuates atherosclerosis and stabilizes plaques in apolipoprotein E-deficient mice

Human Gene Therapy

Volumn 19, Issue 3, 2008, Pages 287-299

  Hu, Qin ^a   Zhang, Xian Jun ^a   Zhang, Cheng ^a   Zhao, Yu Xia ^a   He, Hong ^a   Liu, Chun Xi ^a   Feng, Jin Bo ^a   Jiang, Hong ^a   Yang, Fa Lin ^a   Zhang, Chun Xiang ^b   Zhang, Yun ^a  

^a SHANDONG UNIVERSITY   (China)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; ADENOVIRUS VECTOR; APOLIPOPROTEIN E; CD36 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CHOLESTEROL; COLLAGEN; COMPLEMENTARY DNA; GELATINASE B; GREEN FLUORESCENT PROTEIN; LIPID; LIVER X RECEPTOR ALPHA; MACROPHAGE MIGRATION INHIBITION FACTOR; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATE BUFFERED SALINE; SCAVENGER RECEPTOR A; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; ATTENUATION; CONTROLLED STUDY; FEEDING; GENE OVEREXPRESSION; GENE TARGETING; GENE THERAPY; KNOCKOUT MOUSE; LIPID DIET; MACROPHAGE; MALE; MOUSE; NONHUMAN; SMOOTH MUSCLE FIBER; UPREGULATION;

ADENOVIRIDAE; ANIMALIA; MUS;

EID: 41149093584     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2007.0142.correx     Document Type: Erratum

References (44)

1. ANDERSON, E.A., HOFFMAN, R.P., BALON, T.W., SINKEY, C.A., and MARK, A.L. (1991). Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J. Clin. Invest. 87, 2246-2252.
2. BABAEV, V.R., YANCEY, P.G., RYZHOV, S.V., KON, V., BREYER, M.D., MAGNUSON, M.A., FAZIO, S., and LINTON, M.F. (2005). Conditional knockout of macrophage PPARγ increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 25, 1647-1653.
3. BEAUDEUX, J.L., GIRAL, P., BRUCKERT, E., FOGLIETTI, M.J., and CHAPMAN, M.J. (2003). Matrix metalloproteinases and atherosclerosis: Therapeutic aspects. Ann. Biol. Clin. (Paris) 61, 147-158.
4. BREWER, H.B., JR. (2004). Focus on high-density lipoproteins in reducing cardiovascular risk. Am. Heart J. 148(1 Suppl), S14-S18.
5. BURGER-KENTISCHER, A., GOEBEL, H., SEILER, R., FRAEDRICH, G., SCHAEFER, H.E., DIMMELER, S., KLEEMANN, R., BERNHAGEN, J., and IHLING, C. (2002). Expression of macrophage migration inhibitory factor in different stages of human atherosclerosis. Circulation 105, 1561-1566.
6. CALABRO, P., SAMUDIO, I., SAFE, S.H., WILLERSON, J.T., and YEH, E.T. (2005). Inhibition of tumor-necrosis-factor-α induced endothelial cell activation by a new class of PPAR-γ agonists: An in vitro study showing receptor-independent effects. J. Vasc. Res. 42, 509-516.
7. CHEN, F., ERIKSSON, P., HANSSON, G.K., HERZFELD, I., KLEIN, M., HANSSON, L.O., and VALEN, G. (2005). Expression of matrix metalloproteinase 9 and its regulators in the unstable coronary atherosclerotic plaque. Int. J. Mol. Med. 15, 57-65.
8. CHEN, Z., ISHIBASHI, S., PERREY, S., OSUGA, J., GOTODA, T., KITAMINE, T., TAMURA, Y., OKAZAKI, H., YAHAGI, N., IIZUKA, Y., SHIONOIRI, F., OHASHI, K., HARADA, K., SHIMANO, H., NAGAI, R., and YAMADA, N. (2001). Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: Pleiotropic effects on CD36 expression and HDL. Arterioscler. Thromb. Vasc. Biol. 21, 372-377.
9. CHINETTI, G., GBAGUIDI, F.G., GRIGLIO, S., MALLAT, Z., ANTONUCCI, M., POULAIN, P., CHAPMAN, J., FRUCHART, J.C., TEDGUI, A., NAJIB-FRUCHART, J., and STAELS, B. (2000). CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation 101, 2411-2417.
10. CHOUDHURY, R.P., RONG, J.X., TROGAN, E., ELMALEM, V.I., DANSKY, H.M., BRESLOW, J.L., WITZTUM, J.L., FALLON, J.T., and FISHER, E.A. (2004). High-density lipoproteins retard the progression of atherosclerosis and favorably remodel lesions without suppressing indices of inflammation or oxidation. Arterioscler. Thromb. Vasc. Biol. 24, 1904-1909.
11. DESMET, C., WARZEE, B., GOSSET, P., MELOTTE, D., RONGVAUX, A., GILLET, L., FIEVEZ, L., SEUMOIS, G., VANDERPLASSCHEN, A., STAELS, B., LEKEUX, P., and BUREAU, F. (2005). Pro-inflammatory properties for thiazolidinediones. Biochem. Pharmacol. 69, 255-265.
12. GOUGH, P.J., GOMEZ, I.G., WILLE, P.T., and RAINES, E.W. (2006). Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice. J. Clin. Invest. 116, 59-69.
13. HE, T.C., ZHOU, S., DA COSTA, L.T., YU, J., KINZLER, K.W., and VOGELSTEIN, B. (1998). A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. U.S.A. 95, 2509-2514.
14. INOUE, M., OHTAKE, T., MOTOMURA, W., TAKASHI, N., HOSOKI, Y., MIYOSHI, S., SUZUKI, Y., SAITO, H., KOHGO, Y., and OKUMURA, T. (2005). Increased expression of PPARγ in high fat diet-induced liver steatosis in mice. Biochem. Biophys. Res. Commun. 14, 215-222.
15. INOUE, S., EGASHIRA, K., NI, W., KITAMOTO, S., USUI, M., OTANI, K., ISHIBASHI, M., HIASA, K., NISHIDA, K., and TAKESHITA, A. (2002). Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein E-knockout mice. Circulation 106, 2700-2706.
16. JOYCE, C.W., AMAR, M.J., LAMBERT, G., VAISMAN, B.L., PAIGEN, B., NAJIB-FRUCHART, J., HOYT, R.F., Jr., NEUFELD, E.D., REMALEY, A.T., FREDRICKSON, D.S., BREWER, H.B., Jr., and SANTAMARINA-FOJO, S. (2002). The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice. Proc. Natl. Acad. Sci. U.S.A. 99, 407-412.
17. KINTSCHER, U., GOETZE, S., WAKINO, S., KIM, S., NAGPAL, S., CHANDRARATNA, R.A., GRAF, K., FLECK, E., HSUEH, W.A., and LAW, R.E. (2000). Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes. Eur. J. Pharmacol. 401, 259-270.
18. LI, A.C., BROWN, K.K., SILVESTRE, M.J., WILLSON, T.M., PALINSKI, W., and GLASS, C.K. (2000). Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J. Clin. Invest. 106, 523-531.
19. LIM, S., JIN, C.J., KIM, M., CHUNG, S.S., PARK, H.S., LEE, I.K., LEE, C.T., CHO, Y.M., LEE, H.K., and PARK, K.S. (2006). PPARγ gene transfer sustains apoptosis, inhibits vascular smooth muscle cell proliferation, and reduces neointima formation after balloon injury in rats. Arterioscler. Thromb. Vasc. Biol. 26, 808-813.
20. LUTGENS, E., GORELIK, L., DAEMEN, M.J., DE MUINCK, E.D., GREWAL, I.S., KOTELIANSKY, V.E., and FLAVELL, R.A. (1999). Requirement for CD154 in the progression of atherosclerosis. Nat. Med. 5, 1313-1316.
21. LUTGENS, E., LIEVENS, D., BECKERS, L., DONNERS, M., and DAEMEN, M. (2007). CD40 and its ligand in atherosclerosis. Trends Cardiovasc. Med. 17, 118-123.
22. MARTENS, F.M., VISSEREN, F.L., LEMAY, J., DE KONING, E.J., and RABELINK, T.J. (2002). Metabolic and additional vascular effects of thiazolidinediones. Drugs 62, 1463-1480.
23. MARX, N., SUKHOVA, G., MURPHY, C., LIBBY, P., and PLUTZKY, J. (1998). Macrophages in human atheroma contain PPARγ: Differentiation-dependent peroxisomal proliferator-activated receptor γ (PPARγ) expression and reduction of MMP-9 activity through PPARγ activation in mononuclear phagocytes in vitro. Am. J. Pathol. 153, 17-23.
24. MARX, N., FROEHLICH, J., SIAM, L., ITTNER, J., WIERSE, G., SCHMIDT, A., SCHARNAGL, H., HOMBACH, V., and KOENIG, W. (2003). Antidiabetic PPAR γ-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 23, 283-288.
25. MOORE, K.J., KUNJATHOOR, V.V., KOEHN, S.L., MANNING, J.J., TSENG, A.A., SILVER, J.M., MCKEE, M., and FREEMAN, M.W. (2005). Loss of receptor-mediated lipid uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic mice. J. Clin. Invest. 115, 2192-2201.
26. MORAND, E.F. (2005). New therapeutic target in inflammatory disease: Macrophage migration inhibitory factor. Intern. Med. J. 35, 419-426.
27. OHASHI, R., MU, H., YAO, Q., and CHEN, C. (2005). Cellular and molecular mechanisms of atherosclerosis with mouse models. Trends Cardiovasc. Med. 14, 187-190.
28. ORAM, J.F., and VAUGHAN, A.M. (2000). ABCA1-mediated transport of cellular cholesterol and phospholipids to HDL apolipoproteins. Curr. Opin. Lipidol. 11, 253-260.
29. PASCERI, V., WU, H.D., WILLERSON, J.T., and YEH, E.T. (2000). Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-γ activators. Circulation 101, 235-238.
30. PLUTZKY, J. (2003). Medicine. PPARs as therapeutic targets: Reverse cardiology? Science 302, 406-407.
31. PUDDU, P., PUDDU, G.M., and MUSCARI, A. (2003). Peroxisome proliferator-activated receptors: Are they involved in atherosclerosis progression? Int. J. Cardiol. 90, 133-140.
32. SAINI, H.K., XU, Y.J., ARNEJA, A.S., TAPPIA, P.S., and DHALLA, N.S. (2005). Pharmacological basis of different targets for the treatment of atherosclerosis. J. Cell. Mol. Med. 9, 818-839.
33. SCHOBER, A., BERNHAGEN, J., THIELE, M., ZEIFFER, U., KNARREN, S., ROLLER, M., BUCALA, R., and WEBER, C. (2004). Stabilization of atherosclerotic plaques by blockade of macrophage migration inhibitory factor after vascular injury in apolipoprotein E-deficient mice. Circulation 109, 380-385.
34. SHU, H., WONG, B., ZHOU, G., LI, Y., BERGER, J., WOODS, J.W., WRIGHT, S.D., and CAI, T.Q. (2000). Activation of PPARα or γ reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells. Biochem. Biophys. Res. Commun. 267, 345-349.
35. SINNAEVE, P., VARENNE, O., COLLEN, D., and JANSSENS, S. (1999). Gene therapy in the cardiovascular system: An update. Cardiovasc. Res. 44, 498-506.
36. THAM, D.M., WANG, Y.X., and RUTLEDGE, J.C. (2003). Modulation of vascular inflammation by PPARs. Drug News Perspect. 16, 109-116.
37. TREMOLI, E., CAMERA, M., TOSCHI, V., and COLLI, S. (1999). Tissue factor in atherosclerosis. Atherosclerosis 144, 273-283.
38. VIRMANI, R., KOLODGIE, F.D., BURKE, A.P., FARB, A., and SCHWARTZ, S.M. (2000). Lessons from sudden coronary death: A comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 20, 1262-1275.
39. VON ECKARDSTEIN, A. (2005). Risk factors for atherosclerotic vascular disease. Handb. Exp. Pharmacol. 170, 71-105.
40. WAGNER, B.L., VALLEDOR, A.F., SHAO, G., DAIGE, C.L., BISCHOFF, E.D., PETROWSKI, M., JEPSEN, K., BAEK, S.H., HEYMAN, R.A., ROSENFELD, M.G., SCHULMAN, I.G., and GLASS, C.K. (2003). Promoter-specific roles for liver X receptor/ corepressor complexes in the regulation of ABCA1 and SREBP1 gene expression. Mol. Cell. Biol. 23, 5780-5789.
41. WANG, M., and TAFURI, S. (2003). Modulation of PPARγ activity with pharmaceutical agents: Treatment of insulin resistance and atherosclerosis. J. Cell. Biochem. 89, 38-47.
42. WORLEY, J.R., BAUGH, M.D., HUGHES, D.A., EDWARDS, D.R., HOGAN, A., SAMPSON, M.J., and GAVRILOVIC, J. (2003). Metalloproteinase expression in PMA-stimulated THP-1 cells: Effects of peroxisome proliferator-activated receptor-γ (PPAR γ) agonists and 9-cis-retinoic acid. J. Biol. Chem. 278, 51340-51346.
43. WU, M., and LI, Y.G. (2006). The expression of CD40-CD40L and activities of matrix metalloproteinases in atherosclerotic rats. Mol. Cell. Biochem. 282, 141-146.
44. YU, S., MATSUSUE, K., KASHIREDDY, P., CAO, W.Q., YELDANDI, V., YELDANDI, A.V., RAO, M.S., GONZALEZ, F.J., and REDDY, J.K. (2003). Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor γ1 (PPARγ1) overexpression. J. Biol. Chem. 278, 498-505.